Lundbeckfonden Ventures Overview

Lundbeckfonden Ventures is an evergreen life science venture fund established in 2009 and wholly owned by the Lundbeck Foundation. The firm focuses on investing in early to mid-stage companies within the biotechnology, health tech, and pharmaceutical sectors, with a particular emphasis on projects and companies close to or in clinical development. Operating independently from the Lundbeck Foundation's controlling ownerships in H. Lundbeck A/S, ALK-Abelló A/S, and Falck A/S, Lundbeckfonden Ventures aims to generate returns that support the group's activities. The firm typically invests between €3 million and €10 million per company, with annual investments totaling approximately €50 million. Its portfolio includes companies such as Notify Therapeutics, AFYX Therapeutics, and NMD Pharma, reflecting its commitment to advancing neuroscience discoveries and innovative healthcare solutions. Lundbeckfonden Ventures is headquartered in Copenhagen, Denmark, and maintains an active presence in both Europe and the United States, aligning with its strategic focus on global healthcare innovation.

Is Lundbeckfonden Ventures the right investor for your startup? Browse their investment focus, stage preferences, and geographic scope to see how well they align with your fundraising goals. Your full match score with Lundbeckfonden Ventures, along with a list of other relevant VCs, is available on Hopohopo.io.